Aequs’ IPO saw strong Day 1 demand, getting subscribed 3.42 times, with retail bids soaring past 11 times. The grey market premium suggests a 37% listing upside, indicating a possible debut near Rs 170. Despite recent losses, analysts cite strong aerospace integration, high entry barriers, and attractive valuations as key positives.Read More

Vidya Wires IPO: In the grey market, the IPO is quoting a ₹5 premium — about 9.6% above the upper price band — suggesting a possible listing near ₹57 per share. Investor sentiment remains upbeat, though the premium has eased from 11.54% earlier.Read More

President Donald Trump is intensely focused on lowering interest rates. He has tasked Treasury Secretary Scott Bessent with finding a new Federal Reserve chair. Trump wants swift rate cuts to boost the economy. The selection process is crucial, with potential candidates signaling willingness to align with Trump’s agenda. The chosen nominee faces pressure to deliver.Read More

JPMorgan’s Rajiv Batra says PSU banks remain a top tactical bet despite recent volatility, with strong credit growth, tech upgrades, and policy support set to drive re-rating. FIIs may return as India’s growth, earnings, and reforms strengthen. He expects nominal GDP to rise, supporting 13–14% earnings growth and further upside in midcaps if momentum holds.Read More

The rupee’s drop past 90 per dollar has shaken markets and dragged equities lower, with rate-sensitive sectors hit hardest. Despite strong GDP growth, the currency’s near 5% depreciation this year makes it the worst performer among major EM peers and has revived inflation concerns. Analysts warn that continued weakness could limit the RBI’s scope for...Read More

Corona Remedies is launching its Rs 655 crore IPO next week. The Gujarat-based pharmaceutical firm is offering 100% of its shares. The grey market premium indicates a potential 29% upside. Investors can subscribe from December 8 to 10. The company has strong financial growth and high return ratios. Shares will list on NSE and BSE.Read More

Technical analyst Rohit Srivastava says Nifty is oversold and sitting on a crucial support at 25,900, with Bank Nifty near 59,100. A close below these levels could trigger a deeper fall, but holding them may mark a market bottom. He explains why volatility remains low, sector rotation continues, and what levels traders should watch for...Read More

The Indian rupee has reached a new low, trading below 90 against the US dollar. This marks a significant slide for the currency. Foreign investors are continuing to withdraw funds from Indian stocks. The rupee’s decline is impacting exports and making local equities less attractive. This trend highlights economic challenges for India.Read More

Northern Arc Capital expects its return on assets (ROA) to rise to 3.7–3.8% over the next two years, driven by stronger NIMs from its expanding retail franchise and a fast-growing fee income business. MD & CEO Ashish Mehrotra outlines how credit-cost normalization, branch-led MSME growth and a rising share of direct lending will power 25–30%...Read More

Biocon shares: Biocon’s Board will meet on Saturday, December 6, 2025, to decide on key proposals that could shape its growth and shareholder value. A major agenda item is a potential investment in its unlisted arm, Biocon Biologics either through cash or preferential allotment to boost its stake and support long-term expansion.Read More